Arvinas’ First Quarter 2023 Financial Results and Corporate Update: A Clever and Personable Recap
Clever, personable, and wonderfully unconventional Arvinas Reports First Quarter 2023 Financial Results and Provides Corporate Update Multiple vepdegestrant (ARV-471) studies enrolling globally Arvinas, Inc. has recently shared exciting updates on the progress of their vepdegestrant (ARV-471) studies, which are currently enrolling participants globally. These studies encompass Phase 1, 2, and 3 trials, indicating the company’s…